Rocket Pharmaceuticals ... Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based ...

On Wednesday, Stifel analysts reiterated their Buy rating and $27.00 price target for Rocket Lab USA (NASDAQ:RKLB) shares, which ...

Rocket Lab USA has a jam-packed 2025 schedule filled with new launches as well as acquisitions. Check out why I'm initiating ...

Rocket Pharmaceuticals (NASDAQ:RCKT – Get Free Report) had its price target lifted by stock analysts at Scotiabank from ...

BMO Capital Markets assumed coverage on shares of Rocket Pharmaceuticals (NASDAQ:RCKT – Free Report) in a report released on Wednesday morning, Ratings reports. The brokerage issued an outperform ...

On Thursday, BofA Securities increased its price target for Rocket Lab USA (NASDAQ:RKLB) shares, setting a new goal of $30, up ...